U.S., April 25 -- ClinicalTrials.gov registry received information related to the study (NCT07550816) titled 'Drug-drug Interaction Study of ZT002 Injection in Overweight and Obese Participants' on April 20.
Brief Summary: ZT002 is an ultralong-acting glucagon-like peptide-1. This open-label, fixed sequence, two-period crossover drug-drug interaction study is designed to evaluate the impact of ZT002 on the PK of metformin, warfarin, rosuvastatin and digoxin. The study will include obese and overweight but otherwise healthy participants aged 18 - 45.
The study consists of two cohorts. Each participant can only join one of the cohorts.
Cohort 1 evaluates the impact of ZT002 on the PK of metformin at steady state and on the PK of a single d...